NCT05424835
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients who have not received prior treated with Herceptin/trastuzumab & a taxane in the recurrence or metastasis stage
https://ClinicalTrials.gov/show/NCT05424835